These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26020282)

  • 1. Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.
    Noureddin M; Rotman Y; Zhang F; Park H; Rehermann B; Thomas E; Liang TJ
    Genes Immun; 2015; 16(5):321-9. PubMed ID: 26020282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
    Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
    Estrabaud E; Appourchaux K; Bièche I; Carrat F; Lapalus M; Lada O; Martinot-Peignoux M; Boyer N; Marcellin P; Vidaud M; Asselah T
    PLoS One; 2015; 10(4):e0121395. PubMed ID: 25844942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
    Meissner EG; Kohli A; Virtaneva K; Sturdevant D; Martens C; Porcella SF; McHutchison JG; Masur H; Kottilil S
    J Viral Hepat; 2016 Jul; 23(7):496-505. PubMed ID: 26840694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.
    Amanzada A; Reinhardt L; Fey D; Zeisberg EM; Mihm S
    PLoS One; 2015; 10(11):e0143783. PubMed ID: 26606750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
    Lu YF; Goldstein DB; Urban TJ; Bradrick SS
    Virology; 2015 Feb; 476():334-340. PubMed ID: 25577150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.
    Thomas E; Gonzalez VD; Li Q; Modi AA; Chen W; Noureddin M; Rotman Y; Liang TJ
    Gastroenterology; 2012 Apr; 142(4):978-88. PubMed ID: 22248663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
    O'Connor KS; Parnell G; Patrick E; Ahlenstiel G; Suppiah V; van der Poorten D; Read SA; Leung R; Douglas MW; Yang JY; Stewart GJ; Liddle C; George J; Booth DR
    Genes Immun; 2014 Mar; 15(2):88-94. PubMed ID: 24335707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Interferons Lambda 3 and 4 Induces Identical Response in Human Liver Cell Lines Depending Exclusively on Canonical Signaling.
    Lunova M; Kubovciak J; Smolková B; Uzhytchak M; Michalova K; Dejneka A; Strnad P; Lunov O; Jirsa M
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.
    Rauff B; Amar A; Chudhary SA; Mahmood S; Tayyab GUN; Hanif R
    Arch Virol; 2021 Apr; 166(4):1047-1056. PubMed ID: 33528661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
    Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
    Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
    Fernández-Carrillo C; Coto-Llerena M; González P; Crespo G; Mensa L; Caro-Pérez N; Gambato M; Navasa M; Forns X; Pérez-del-Pulgar S
    J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.
    Abe H; Hayes CN; Ochi H; Tsuge M; Miki D; Hiraga N; Imamura M; Takahashi S; Kubo M; Nakamura Y; Kamatani N; Chayama K
    J Med Virol; 2011 Sep; 83(9):1597-607. PubMed ID: 21739451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples.
    Amanzada A; Kopp W; Spengler U; Ramadori G; Mihm S
    PLoS One; 2013; 8(12):e84026. PubMed ID: 24376784
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Roy N; Prasad C; Kumar A; Mondol K; Jain K; Yadav R; Jha JK; Nadda N; Acharya SK; Shalimar ; Nayak B
    Virusdisease; 2019 Sep; 30(3):344-353. PubMed ID: 31803800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.